GSK’s Heart Drug Flops in Phase III Clinical Trial

A A
GlaxoSmithKline’s experimental coronary heart disease drug darapladib failed to reduce heart attacks, strokes and major cardiovascular events in a closely watched Phase III clinical trial, deflating some expectations for GSK’s Phase III pipeline.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00